Anabel is a Reporter, working across the six Citeline publications. She is a recent graduate from the University of Exeter and holds a BA English degree. Since graduating, Anabel has also completed an editorial internship with the In Vivo team. Before joining Norstella she spent the past year as Editor-in-Chief of her university’s student paper, Exeposé, managing an editorial team to produce a 32-page paper on a fortnightly basis.
Latest from Anabel Costa-Ferreira
The Australian Therapeutic Goods Administration proposed a narrower indication that Eisai rejected.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.
Steven Damon, Micron Biomedical CEO, discusses the promising future of Micron’s microneedle technology, which allows for painless vaccine delivery through pressing a small patch onto the skin.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.